Prostatype Genomics AB (OSTO:PROGEN) Asset Turnover: 0.01 (As of Dec. 2025)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.43
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Asset Turnover?

Prostatype Genomics AB OSTO:PROGEN -4.23% 25 Asset Turnover is 0.01 as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Prostatype Genomics AB's Revenue for the six months ended in Dec. 2025 was kr0.35 Mil. Prostatype Genomics AB's Total Assets for the quarter that ended in Dec. 2025 was kr47.35 Mil. Therefore, Prostatype Genomics AB's Asset Turnover for the quarter that ended in Dec. 2025 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Prostatype Genomics AB's annualized ROE % for the quarter that ended in Dec. 2025 was -130.66%. It is also linked to ROA % through Du Pont Formula. Prostatype Genomics AB's annualized ROA % for the quarter that ended in Dec. 2025 was -86.94%.


Prostatype Genomics AB  (OSTO:PROGEN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Prostatype Genomics AB's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-41.166/31.507
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-41.166 / 0.696)*(0.696 / 47.351)*(47.351/ 31.507)
=Net Margin %*Asset Turnover*Equity Multiplier
=-5914.66 %*0.0147*1.5029
=ROA %*Equity Multiplier
=-86.94 %*1.5029
=-130.66 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Prostatype Genomics AB's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-41.166/47.351
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-41.166 / 0.696)*(0.696 / 47.351)
=Net Margin %*Asset Turnover
=-5914.66 %*0.0147
=-86.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Prostatype Genomics AB Asset Turnover Related Terms


Prostatype Genomics AB Asset Turnover Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Asset Turnover Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial 0.00 0.02 0.03 0.00 0.01

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.00 0.01 0.01

OSTO:PROGEN vs TMO, DHR, IDXX: Asset Turnover Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB Asset Turnover vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Asset Turnover falls into.


OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Prostatype Genomics AB's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=0.594/( (41.97+50.862)/ 2 )
=0.594/46.416
=0.01

Prostatype Genomics AB's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.348/( (43.84+50.862)/ 2 )
=0.348/47.351
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.01 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Asset Turnover of 0.01 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Asset Turnover too high?
Prostatype Genomics AB's current Asset Turnover is 0.01. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Asset Turnover compare to TMO and DHR?
Prostatype Genomics AB's Asset Turnover of 0.01 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Diagnostics & Research company?
A good Asset Turnover depends on the Medical Diagnostics & Research industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Asset Turnover is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Asset Turnover is 0.01. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Asset Turnover is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Asset Turnover: 0.01
  • GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.43
Price
kr0.11
GF Value